GlassScriptPhysician profile
Bekir Melek
NPI 1114033917
$2,043.05
in general payments reported to CMS, 2019-2025
26 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $285 · 2021: $168 · 2022: $132 · 2023: $647 · 2024: $306 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $316.23 | 2021-2025 | Aveir, Jot Dx, Merlin@Home |
| Boston Scientific Corporation | $268.54 | 2021-2025 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Cds - Mct/Cem Monitoring |
| Novartis Pharmaceuticals Corporation | $225.79 | 2019-2024 | |
| Medtronic, INC. | $209.28 | 2021-2024 | Linq II |
| Biotronik INC. | $140.40 | 2019 | |
| Philips North America LLC | $103.84 | 2023-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Ck4) Mcot |
| Pfizer INC. | $100.49 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $100.00 | 2023 | Andexxa |
| Medtronic Vascular, INC. | $80.22 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $75.43 | 2022-2024 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $55.69 | 2025 | Sapien 3 Ultra Resilia |
| Kestra Medical Technology Services, INC. | $53.23 | 2024-2025 | Assure Wcd |
| Baxter Healthcare | $47.63 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $43.67 | 2024 | Onpattro |
| Cvrx, INC. | $28.92 | 2024 | Barostim Neo System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $28.35 | 2024 | Arcalyst |
| Abiomed | $24.08 | 2024 | Impella |
| Sanofi-Aventis U.S. LLC | $22.38 | 2021 | |
| Convatec INC. | $21.64 | 2022 | |
| Cardiva Medical, INC. | $19.59 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $16.51 | 2023 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $15.61 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.34 | 2025 | Jardiance |
| Amarin Pharma, INC. | $13.99 | 2019 | |
| Bardy Diagnostics, INC. | $9.85 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7.35 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bekir Melek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.